Antheia utilizes synthetic biology to revolutionize the production of essential medicines by creating biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This innovative approach addresses the inefficiencies and unpredictability of traditional agricultural sources, which are often vulnerable to climate change and other environmental factors. By employing contained fermentation environments, Antheia ensures a more reliable and consistent supply of pharmaceutical ingredients, significantly reducing the timelines for production from years to weeks. This method not only enhances the efficiency of pharmaceutical manufacturing but also minimizes the environmental footprint associated with conventional agricultural practices.

The company's biomanufacturing platform is designed to support scalable and resilient pharmaceutical supply chains, enabling rapid-response manufacturing and equitable access to critical medicines. Antheia's focus on engineering complex biosynthesis pathways in microorganisms, such as yeast, allows for the production of pharmaceutical ingredients that are otherwise challenging to synthesize through traditional chemical methods. This advanced technology positions Antheia at the forefront of the synthetic biology field, promising to transform drug development and discovery while addressing the urgent need for reliable access to essential medicines worldwide.

United States

Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio. 

Antheia

Company Details